Top Story

AMPK activator reduces glucose level in type 2 diabetes in phase 2a trial

November 18, 2017

A novel AMP-activated protein kinase activator showed glucose reduction and decreased cardiovascular risk factors in people with type 2 diabetes in a phase 2a trial, according to a press release from the drug’s developer.

The first-in-class drug (O304, Betagenon/Baltic Bio) activates AMP-activated protein kinase (AMPK), which regulates energy balance. By activating this protein, the researchers aimed to prevent type 2 diabetes and cardiovascular disease.

In the Journals

Nearly 1 in 7 patients with diabetes have poor glycemic control

November 17, 2017
About one in seven patients with diabetes had poor glycemic control between 2007 and 2014 despite an increase in the frequency of self-reported testing and patient…
In the Journals Plus

Patients with Addison's disease show no increase in adipose tissue

November 17, 2017
Although patients with Addison’s disease who were treated with glucocorticoids demonstrated increased cortisol exposure, they did not have increased levels of
In the Journals PlusPerspective

Heart failure strongest predictor of poor survival in type 2 diabetes

November 17, 2017
Older adults with type 2 diabetes are at increased risk for death from cardiovascular complications, with the strongest associations found between survival and heart…
In the Journals Plus

Glycemic control, drug regimen interaction influence mortality risk in type 2 diabetes

November 17, 2017
Adults with type 2 diabetes who achieve low HbA1c targets may have an increased risk for death, particularly when treated with regimens associated with hypoglycemia…
More Headlines »

The Future of the Lipid Panel: An NLA Expert Discussion

This educational activity is supported by an educational grant from Quest Diagnostics, Inc.

Past-President of the National Lipid Association and Editor-in-Chief of the Journal of Clinical Lipidology, Dr. W…
More »
Meeting News

VIDEO: ‘Dysmobility syndrome’ provides better understanding of fracture than osteoporosis alone

October 16, 2017
More »
Resource Centers



What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Lipid Association.

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia and…
More »
Current Issues
View the Current Issue